NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/02/2025
Voltar para busca
Dado oficial do USPTO
OPTIDART
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
45
Atualização mais recente
08/02/2025
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
17/05/2019
Data de registro
28/12/2021
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
28/12/2021
Última transação
08/02/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
98
Localização do titular
KR
Examinador
O'BRIEN, JENNIFER
Unidade examinadora
N20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Genexine, Inc.
Representantes
James R Menker Holley & Menker, PA
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; vaccines; adjuvants for use with vaccines; vaccine preparations; anti-inflammatories; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations for the treatment of inflammatory diseases; nucleic acid sequences for medical and veterinary purposes; diagnostic preparations for medical purposes for detecting mutation in prion genes; chemical preparations for use in DNA analysis for medical purposes; reagents for use in medical genetic testing; human vaccine preparations; pharmaceutical preparations for the treatment of cervical intraepithelial neoplasia; pharmaceutical preparations for the treatment of immune system related diseases and disorders; anti-asthmatic agentspharmaceutical preparations for the treatment of asthmatic disorders; dermatological pharmaceutical products; antibiotic preparations; biological preparationsantibody fusion proteins for the treatment of cancer
Publicações
Histórico de despachos e eventos da marca no USPTO.
45 publicações encontradas
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
28/11/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/07/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/06/2022
FIMP
FINAL DISPOSITION PROCESSED
09/06/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
28/03/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
28/12/2021
GPNX
NOTIFICATION PROCESSED BY IB
24/10/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/10/2021
PUBO
PUBLISHED FOR OPPOSITION
12/10/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
22/09/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
22/09/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/09/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/09/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/08/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/08/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
26/08/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
14/07/2021
GNRT
NON-FINAL ACTION E-MAILED
14/07/2021
CNRT
NON-FINAL ACTION WRITTEN
14/07/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/05/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/05/2021
ALIE
ASSIGNED TO LIE
25/05/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
19/05/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
30/01/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/01/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
13/01/2021
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
12/11/2020
ALIE
ASSIGNED TO LIE
12/11/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
28/05/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
01/04/2020
GNSL
LETTER OF SUSPENSION E-MAILED
01/04/2020
CNSL
SUSPENSION LETTER WRITTEN
01/04/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/03/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/03/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/03/2020
RFNT
REFUSAL PROCESSED BY IB
28/09/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/09/2019
RFRR
REFUSAL PROCESSED BY MPU
11/09/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
27/08/2019
CNRT
NON-FINAL ACTION WRITTEN
26/08/2019
MAFR
APPLICATION FILING RECEIPT MAILED
24/08/2019
DOCK
ASSIGNED TO EXAMINER
20/08/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/08/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/08/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace OPTIDART ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.